Sign Up
Stories
89bio to Present pegozafermin for NASH and SHTG Treatment at Healthcare Conference
Share
Advancements in Cancer Treatment and Mar...
Amgen's Obesity Prospects and Q4 Results...
AnaMar Receives Orphan Drug Designation ...
ANJESO Drug Insight and Market Forecast
Anima Biotech's Promising Lung Fibrosis ...
Aquadex SmartFlow® System's Potential
Overview
API
89bio, Inc. will present its lead candidate, pegozafermin, at the Oppenheimer 34th Annual Healthcare Life Sciences Conference for the treatment of NASH and SHTG. The company is based in San Francisco.
Ask a question
How does pegozafermin work to address these conditions?
What are the potential benefits of pegozafermin for the treatment of NASH and SHTG?
What other research or development is being done in the field of NASH and SHTG?
Article Frequency
0.2
0.4
0.6
0.8
1.0
Nov 2023
Dec 2023
Jan 2024
Coverage